{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:42:39Z","timestamp":1791398559201,"version":"4.3.3"},"reference-count":35,"publisher":"The Company of Biologists","issue":"1","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":1707,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Proprotein convertase subtilisin kexin type 9 (PCSK9) is a critical modulator of cholesterol homeostasis. Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL). However, limitations of the currently available cellular models preclude deciphering the consequences of PCSK9 mutation further. We aimed to validate urine-sample-derived human induced pluripotent stem cells (UhiPSCs) as an appropriate tool to model PCSK9-mediated ADH and FHBL. To achieve our goal, urine-sample-derived somatic cells were reprogrammed into hiPSCs by using episomal vectors. UhiPSC were efficiently differentiated into hepatocyte-like cells (HLCs). Compared to control cells, cells originally derived from an individual with ADH (HLC-S127R) secreted less PCSK9 in the media (\u221238.5%; P=0.038) and had a 71% decrease (P&amp;lt;0.001) of low-density lipoprotein (LDL) uptake, whereas cells originally derived from an individual with FHBL (HLC-R104C\/V114A) displayed a strong decrease in PCSK9 secretion (\u221289.7%; P&amp;lt;0.001) and had a 106% increase (P=0.0104) of LDL uptake. Pravastatin treatment significantly enhanced LDL receptor (LDLR) and PCSK9 mRNA gene expression, as well as PCSK9 secretion and LDL uptake in both control and S127R HLCs. Pravastatin treatment of multiple clones led to an average increase of LDL uptake of 2.19\u00b10.77-fold in HLC-S127R compared to 1.38\u00b10.49 fold in control HLCs (P&amp;lt;0.01), in line with the good response to statin treatment of individuals carrying the S127R mutation (mean LDL cholesterol reduction=60.4%, n=5). In conclusion, urine samples provide an attractive and convenient source of somatic cells for reprogramming and hepatocyte differentiation, but also a powerful tool to further decipher PCSK9 mutations and function.<\/jats:p>","DOI":"10.1242\/dmm.022277","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T01:03:18Z","timestamp":1450400598000},"page":"81-90","source":"Crossref","is-referenced-by-count":44,"title":["Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia"],"prefix":"10.1242","volume":"9","author":[{"given":"Karim","family":"Si-Tayeb","sequence":"first","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Idriss","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"},{"name":"5 ER045 - Laboratory of Stem Cells, PRASE, DSST, Beirut, Lebanon"},{"name":"Lebanese University 6 Biology Department, Faculty of Sciences-I , , Beirut 6573\/14 , Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoite","family":"Champon","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Caillaud","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Pichelin","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"},{"name":"CHU Nantes 4 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax, CIC Endocrinology-Nutrition 4 , , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Arnaud","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lemarchand","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Le May","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Zibara","sequence":"additional","affiliation":[{"name":"5 ER045 - Laboratory of Stem Cells, PRASE, DSST, Beirut, Lebanon"},{"name":"Lebanese University 6 Biology Department, Faculty of Sciences-I , , Beirut 6573\/14 , Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"INSERM, UMR1087 1 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax 1 , , Nantes F-44000 , France"},{"name":"CNRS, UMR 6291 2 , Nantes F-44000 , France"},{"name":"Universit\u00e9 de Nantes 3 , Nantes F-44000 , France"},{"name":"CHU Nantes 4 , , Nantes F-44000 , France"},{"name":"L\u2019institut du thorax, CIC Endocrinology-Nutrition 4 , , Nantes F-44000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","reference":[{"key":"2024061302500045500_DMM022277C1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"2024061302500045500_DMM022277C2","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2024061302500045500_DMM022277C3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2024061302500045500_DMM022277C4","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1002\/stem.1424","article-title":"Multi-potential differentiation of human urine-derived stem cells: potential for therapeutic applications in urology","volume":"31","author":"Bharadwaj","year":"2013","journal-title":"Stem Cells"},{"key":"2024061302500045500_DMM022277C5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2024061302500045500_DMM022277C6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","article-title":"Effect of mutations in the PCSK9 gene on the cell surface LDL receptors","volume":"15","author":"Cameron","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"2024061302500045500_DMM022277C7","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"key":"2024061302500045500_DMM022277C8","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2024061302500045500_DMM022277C9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"key":"2024061302500045500_DMM022277C10","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/hep.25871","article-title":"JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia","volume":"56","author":"Cayo","year":"2012","journal-title":"Hepatology"},{"key":"2024061302500045500_DMM022277C11","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2024061302500045500_DMM022277C12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tibs.2008.06.005","article-title":"PCSK9 and LDL cholesterol: unravelling the target to design the bullet","volume":"33","author":"Costet","year":"2008","journal-title":"Trends Biochem. Sci."},{"key":"2024061302500045500_DMM022277C13","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1242\/dev.062547","article-title":"HNF4A is essential for specification of hepatic progenitors from human pluripotent stem cells","volume":"138","author":"DeLaForest","year":"2011","journal-title":"Development"},{"key":"2024061302500045500_DMM022277C14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MOL.0b013e3283613a3d","article-title":"PCSK9 inhibitors","volume":"24","author":"Farnier","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"2024061302500045500_DMM022277C15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ajpath.2013.09.026","article-title":"Human induced pluripotent stem cells in hepatology: beyond the proof of concept","volume":"184","author":"Gerbal-Chaloin","year":"2014","journal-title":"Am. J. Pathol."},{"key":"2024061302500045500_DMM022277C16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/00365510600672775","article-title":"Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene","volume":"66","author":"Holla","year":"2006","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"2024061302500045500_DMM022277C17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40139-015-0067-1","article-title":"From human-induced pluripotent stem cells to liver disease modeling: a focus on dyslipidemia","volume":"3","author":"Idriss","year":"2015","journal-title":"Curr. Pathobiol. Rep."},{"key":"2024061302500045500_DMM022277C18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"2024061302500045500_DMM022277C19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"2024061302500045500_DMM022277C20","doi-asserted-by":"publisher","first-page":"e53980","DOI":"10.1371\/journal.pone.0053980","article-title":"Self-renewal and differentiation capacity of urine-derived stem cells after urine preservation for 24 hours","volume":"8","author":"Lang","year":"2013","journal-title":"PLoS ONE"},{"key":"2024061302500045500_DMM022277C21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/eurheartj\/ehu095","article-title":"The Sirt1 activator SRT3025 provides atheroprotection in Apoe-\/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression","volume":"36","author":"Miranda","year":"2015","journal-title":"Eur. Heart J."},{"key":"2024061302500045500_DMM022277C22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1194\/jlr.M800049-JLR200","article-title":"Functional analysis of sites within PCSK9 responsible for hypercholesterolemia","volume":"49","author":"Pandit","year":"2008","journal-title":"J. Lipid Res."},{"key":"2024061302500045500_DMM022277C23","doi-asserted-by":"publisher","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2024061302500045500_DMM022277C24","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024061302500045500_DMM022277C25","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1172\/JCI43122","article-title":"Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells","volume":"120","author":"Rashid","year":"2010","journal-title":"J. Clin. Invest."},{"key":"2024061302500045500_DMM022277C26","doi-asserted-by":"publisher","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by Proprotein Convertase Subtilisin\/Kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2024061302500045500_DMM022277C27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2217\/fca.13.107","article-title":"Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody","volume":"10","author":"Roth","year":"2014","journal-title":"Future Cardiol."},{"key":"2024061302500045500_DMM022277C28","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024061302500045500_DMM022277C29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"2024061302500045500_DMM022277C30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.23354","article-title":"Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells","volume":"51","author":"Si-Tayeb","year":"2010","journal-title":"Hepatology"},{"key":"2024061302500045500_DMM022277C31","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1161\/ATVBAHA.113.301517","article-title":"Hepatic cholesterol homeostasis: is the low-density lipoprotein pathway a regulatory or a shunt pathway?","volume":"33","author":"Sniderman","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2024061302500045500_DMM022277C32","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","article-title":"Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia","volume":"14","author":"Sun","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"2024061302500045500_DMM022277C33","doi-asserted-by":"publisher","first-page":"e70573","DOI":"10.1371\/journal.pone.0070573","article-title":"Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells","volume":"8","author":"Xue","year":"2013","journal-title":"PLoS ONE"},{"key":"2024061302500045500_DMM022277C34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"2024061302500045500_DMM022277C35","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/nprot.2012.115","article-title":"Generation of human induced pluripotent stem cells from urine samples","volume":"7","author":"Zhou","year":"2012","journal-title":"Nat. Protoc."}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/9\/1\/81\/3485507\/dmm022277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.022277\/2069402\/dmm_022277v1.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/9\/1\/81\/3485507\/dmm022277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T02:50:18Z","timestamp":1718247018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/9\/1\/81\/3755\/Urine-sample-derived-human-induced-pluripotent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.022277","relation":{},"ISSN":["1754-8411","1754-8403"],"issn-type":[{"value":"1754-8411","type":"electronic"},{"value":"1754-8403","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,1]]}}}